SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital Mycoplasma genitalium infection

Harrison, MA; Harding-Esch, EM; Marks, M; Pond, MJ; Butcher, R; Solomon, AW; Zhou, L; Tan, N; Nori, AV; Kako, H; et al. Harrison, MA; Harding-Esch, EM; Marks, M; Pond, MJ; Butcher, R; Solomon, AW; Zhou, L; Tan, N; Nori, AV; Kako, H; Sokana, O; Mabey, DCW; Sadiq, ST (2019) Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital Mycoplasma genitalium infection. Sex Transm Infect, 95 (7). pp. 522-528. ISSN 1472-3263 https://doi.org/10.1136/sextrans-2018-053938
SGUL Authors: Sadiq, Syed Tariq Harding-Esch, Emma Michele

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (599kB) | Preview
[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution.

Download (416kB) | Preview

Abstract

Background Mass drug administration (MDA) of 20 mg/kg (maximum 1 g in adults) azithromycin for ocular Chlamydia trachomatis (CT) infection is a key component of the WHO trachoma elimination strategy. However, this dose may be suboptimal in Mycoplasma genitalium infection and may encourage emergence of antimicrobial resistance (AMR) to azithromycin. Objectives To determine the effect of MDA for trachoma elimination on M. genitalium prevalence, strain type and azithromycin resistance. Methods A secondary analysis of CT-negative vulvovaginal swabs from three outpatient antenatal clinics (Honiara, Solomon Islands) from patients recruited either pre-MDA, or 10 months post-MDA in two cross-sectional surveys was carried out. Swabs were tested for M. genitalium infection using Fast Track Diagnostics Urethritis Plus nucleic acid amplification assay. M. genitalium-positive samples were subsequently tested for azithromycin resistance by sequencing domain V of the 23S rRNA DNA region of M. genitalium and underwent phylogenetic analysis by dual locus sequence typing. Results M. genitalium prevalence was 11.9% (28/236) in women pre-MDA and 10.9% (28/256) 10 months post-MDA (p=0.7467). Self-reported receipt of azithromycin as part of MDA was 49.2% in women recruited post-MDA and 17.9% (5/28) in those who tested M. genitalium positive. Of samples sequenced (21/28 pre-MDA, 22/28 post-MDA), all showed a macrolide susceptible genotype. Strain typing showed that sequence types diverged into two lineages, with a suggestion of strain replacement post-MDA. Conclusion A single round of azithromycin MDA in an island population with high baseline M. genitalium prevalence did not appear to impact on either prevalence or azithromycin resistance, in contrast to reported decreased genital CT prevalence in the same population. This may be due to limitations such as sample size, including CT-negative samples only, and low MDA coverage. Further investigation of the impact of multiple rounds of MDA on M. genitalium azithromycin AMR in antibiotic experienced and naïve populations is warranted.

Item Type: Article
Additional Information: © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Keywords: Mycoplasma genitalium, antimicrobial resistance, azithromycin, drug resistance, infection, mass drug administration, mycoplasma, trachoma, 1103 Clinical Sciences, 1117 Public Health And Health Services, 1108 Medical Microbiology, Public Health
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Sex Transm Infect
ISSN: 1472-3263
Language: eng
Dates:
DateEvent
17 October 2019Published
13 April 2019Published Online
24 March 2019Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
II-LB-0214-20005National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
G0901608Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
522Royal Society of Tropical Medicine and Hygienehttp://dx.doi.org/10.13039/501100000683
WT 102807Wellcome Trusthttp://dx.doi.org/10.13039/100004440
WT 098521Wellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 30981999
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/110768
Publisher's version: https://doi.org/10.1136/sextrans-2018-053938

Actions (login required)

Edit Item Edit Item